Valbiotis SAS (PA:ALVAL) — Market Cap & Net Worth
Market Cap & Net Worth: Valbiotis SAS (ALVAL)
Valbiotis SAS (PA:ALVAL) has a market capitalization of $27.68 Million (€23.68 Million) as of September 24, 2026. Listed on the PA stock exchange, this France-based company holds position #24138 globally and #385 in its home market, demonstrating a -3.58% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Valbiotis SAS's stock price €0.73 by its total outstanding shares 35492168 (35.49 Million). Also see ALVAL asset base for a full breakdown of the balance sheet.
Valbiotis SAS Market Cap History: 2017 to 2026
Valbiotis SAS's market capitalization history from 2017 to 2026. Data shows change from $263.19 Million to $30.21 Million (-24.48% CAGR). Also see ALVAL cash flow conversion for how efficiently the company converts equity into cash flow.
Valbiotis SAS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Valbiotis SAS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Valbiotis SAS stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
31.82x
Valbiotis SAS's market cap is 31.82 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $263.19 Million | $3.00K | -$2.44 Million | 87730.92x | N/A |
| 2018 | $134.06 Million | $79.00K | -$4.97 Million | 1697.00x | N/A |
| 2019 | $92.95 Million | $91.00K | -$5.50 Million | 1021.39x | N/A |
| 2020 | $251.45 Million | $3.09 Million | -$3.83 Million | 81.32x | N/A |
| 2021 | $284.23 Million | $298.00K | -$8.68 Million | 953.81x | N/A |
| 2022 | $149.38 Million | $785.00K | -$12.31 Million | 190.29x | N/A |
| 2023 | $207.47 Million | $4.73 Million | -$7.37 Million | 43.83x | N/A |
| 2024 | $63.07 Million | $175.00K | -$10.03 Million | 360.41x | N/A |
| 2025 | $28.80 Million | $905.00K | -$9.42 Million | 31.82x | N/A |
Competitor Companies of ALVAL by Market Capitalization
Companies near Valbiotis SAS in the global market cap rankings as of September 24, 2026. Review Valbiotis SAS (ALVAL) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Valbiotis SAS by market ranking:
- Nestlé S.A (F:NESM): Ranked #90 globally with a market cap of $224.33 Billion USD ( €191.89 Billion EUR).
- Nestle S.A. (SW:NESN): Ranked #104 globally with a market cap of $199.45 Billion USD ( CHF157.76 Billion CHF).
- Danone SA (PA:BN): Ranked #593 globally with a market cap of $45.85 Billion USD ( €39.22 Billion EUR).
- Danone SA (F:BSND): Ranked #700 globally with a market cap of $39.61 Billion USD ( €33.88 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Nestlé S.A | F:NESM | $224.33 Billion | €81.60 |
| #104 | Nestle S.A. | SW:NESN | $199.45 Billion | CHF77.09 |
| #593 | Danone SA | PA:BN | $45.85 Billion | €60.90 |
| #700 | Danone SA | F:BSND | $39.61 Billion | €11.90 |
Valbiotis SAS Historical Marketcap From 2017 to 2026
Between 2017 and today, Valbiotis SAS's market cap moved from $263.19 Million to $ 30.21 Million, with a yearly change of -24.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €30.21 Million | +4.90% |
| 2025 | €28.80 Million | -54.34% |
| 2024 | €63.07 Million | -69.60% |
| 2023 | €207.47 Million | +38.89% |
| 2022 | €149.38 Million | -47.45% |
| 2021 | €284.23 Million | +13.04% |
| 2020 | €251.45 Million | +170.54% |
| 2019 | €92.95 Million | -30.67% |
| 2018 | €134.06 Million | -49.06% |
| 2017 | €263.19 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Valbiotis SAS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $27.68 Million USD |
| MoneyControl | $27.68 Million USD |
| MarketWatch | $27.68 Million USD |
| marketcap.company | $27.68 Million USD |
| Reuters | $27.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Valbiotis SAS
Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; T… Read more